Senseonics has unveiled its strategic roadmap for expanding the reach of its implantable continuous glucose monitoring (CGM) systems, including timelines for next-generation products. During an analyst event at the American Diabetes Association’s 85th Scientific Sessions in Chicago, the company discussed its commercial plans for the Eversense 365 and teased developments in its upcoming Gemini and Freedom platforms.
Launched in October 2024, the Eversense 365 CGM provides year-long glucose monitoring and is distributed globally through Ascensia Diabetes Care. With recent fundraising efforts—including a public offering and a private placement involving CGM giant Abbott—Senseonics now aims to accelerate the system’s commercial ramp-up. The company intends to channel new capital into direct-to-consumer initiatives and marketing, targeting greater patient awareness to complement Ascensia’s 200-person CGM sales team.
Senseonics also announced a key partnership with Sequel Med Tech for integration with automated insulin delivery systems, signaling a broader ecosystem strategy. Additional pump collaborations are anticipated in the future.
“It’s a very exciting time for the company,” said Tim Goodnow, President and CEO of Senseonics. “We really feel that we’re now at the point where we have the technology on Eversense 365 that enables us [to drive shareholder value].”
The company expects its newly secured funding to support product pipeline development and sustain operations through the commercialization of next-gen platforms, with fiscal 2027 set as a key milestone.
Follow MEDWIRE.AI for updates on CGM technology and diabetes innovation.
